CDT Equity (CDT) Total Equity: History & Chart

CDT Equity Inc.(CDT)

Biotechnology · Naples, FL

$0.90-0.02 (-1.68%)

Delayed quote: Oct 6, 2026, 3:38 PM EDT

About CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Naples, FL

4 employees

www.cdtequity.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jamie Bligh

View full financials

Total Equity

Basis: latest reported fiscal quarter. Source: stored company filings; unavailable inputs remain N/A.

The latest quarterly total equity is $1.38B with QoQ Growth of +7.92%. Total equity, also called shareholders' equity, is assets minus liabilities. The book value in P/B is the part attributable to common shareholders: total equity minus preferred stock.

Total Equity

CDT Total Equity

$1.38B

Reported quarterly total equity; no daily interpolation. Q2 FY2026 (2026-06-30): $1.38B.

≈67149x over 10Y

CDT P/B Ratio

Full P/B Ratio page

P/B Ratio

CDT P/B Ratio Chart

0.00

FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock) Quote observation: 2026-10-06T19:41:00.017Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.

Quarterly Total Equity History

Period	Total Equity	QoQ Growth	YoY Growth
Q2 FY2026Period end 2026-06-30	$1.38B	+7.92%	N/A
Q1 FY2026Period end 2026-03-29	$1.28B	N/A	N/A
Q4 FY2025Period end 2025-12-31	$1.26B	+29456.43%	N/A
Q3 FY2025Period end 2025-09-28	$4.28M	+21.22%	N/A
Q2 FY2025Period end 2025-06-29	$3.53M	+31.34%	N/A
Q1 FY2025Period end 2025-03-30	$2.69M	N/A	N/A
Q4 FY2024Period end 2024-12-31	($6.79M)	+25.50%	N/A
Q3 FY2024Period end 2024-09-29	($9.12M)	(66.94%)	(743.48%)
Q2 FY2024Period end 2024-06-30	($5.46M)	(76.25%)	N/A
Q1 FY2024Period end 2024-03-31	($3.10M)	N/A	N/A
Q4 FY2023Period end 2023-12-31	($457,000)	+57.72%	+95.47%
Q3 FY2023Period end 2023-09-30	($1.08M)	N/A	N/A
Q2 FY2023Period end 2023-06-30	$17.04M	(1.98%)	(87.06%)
Q1 FY2023Period end 2023-03-31	$17.38M	N/A	(86.81%)
Q4 FY2022Period end 2022-12-31	($10.09M)	N/A	N/A
Q3 FY2022Period end 2022-09-30	$131.91M	+0.16%	N/A
Q2 FY2022Period end 2022-06-30	$131.70M	(0.09%)	N/A
Q1 FY2022Period end 2022-03-31	$131.82M	N/A	N/A
Q4 FY2021Period end 2021-12-31	$20,619	N/A	N/A

Growth uses unique fiscal quarters. Missing or ambiguous prior periods render N/A.